Cargando…
Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection
Prostate Specific Antigen (PSA) is the most commonly used serum marker for prostate cancer (PCa), although it is not specific and sensitive enough to allow the differential diagnosis of the more aggressive tumors. For that, new diagnostic methods are being developed, such as PCA-3, PSA isoforms that...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412429/ https://www.ncbi.nlm.nih.gov/pubmed/28420168 http://dx.doi.org/10.3390/ijms18040845 |
_version_ | 1783233000340717568 |
---|---|
author | Ferrer-Batallé, Montserrat Llop, Esther Ramírez, Manel Aleixandre, Rosa Núria Saez, Marc Comet, Josep de Llorens, Rafael Peracaula, Rosa |
author_facet | Ferrer-Batallé, Montserrat Llop, Esther Ramírez, Manel Aleixandre, Rosa Núria Saez, Marc Comet, Josep de Llorens, Rafael Peracaula, Rosa |
author_sort | Ferrer-Batallé, Montserrat |
collection | PubMed |
description | Prostate Specific Antigen (PSA) is the most commonly used serum marker for prostate cancer (PCa), although it is not specific and sensitive enough to allow the differential diagnosis of the more aggressive tumors. For that, new diagnostic methods are being developed, such as PCA-3, PSA isoforms that have resulted in the 4K score or the Prostate Health Index (PHI), and PSA glycoforms. In the present study, we have compared the PHI with our recently developed PSA glycoform assay, based on the determination of the α2,3-sialic acid percentage of serum PSA (% α2,3-SA), in a cohort of 79 patients, which include 50 PCa of different grades and 29 benign prostate hyperplasia (BPH) patients. The % α2,3-SA could distinguish high-risk PCa patients from the rest of patients better than the PHI (area under the curve (AUC) of 0.971 vs. 0.840), although the PHI correlated better with the Gleason score than the % α2,3-SA. The combination of both markers increased the AUC up to 0.985 resulting in 100% sensitivity and 94.7% specificity to differentiate high-risk PCa from the other low and intermediate-risk PCa and BPH patients. These results suggest that both serum markers complement each other and offer an improved diagnostic tool to identify high-risk PCa, which is an important requirement for guiding treatment decisions. |
format | Online Article Text |
id | pubmed-5412429 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-54124292017-05-05 Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection Ferrer-Batallé, Montserrat Llop, Esther Ramírez, Manel Aleixandre, Rosa Núria Saez, Marc Comet, Josep de Llorens, Rafael Peracaula, Rosa Int J Mol Sci Article Prostate Specific Antigen (PSA) is the most commonly used serum marker for prostate cancer (PCa), although it is not specific and sensitive enough to allow the differential diagnosis of the more aggressive tumors. For that, new diagnostic methods are being developed, such as PCA-3, PSA isoforms that have resulted in the 4K score or the Prostate Health Index (PHI), and PSA glycoforms. In the present study, we have compared the PHI with our recently developed PSA glycoform assay, based on the determination of the α2,3-sialic acid percentage of serum PSA (% α2,3-SA), in a cohort of 79 patients, which include 50 PCa of different grades and 29 benign prostate hyperplasia (BPH) patients. The % α2,3-SA could distinguish high-risk PCa patients from the rest of patients better than the PHI (area under the curve (AUC) of 0.971 vs. 0.840), although the PHI correlated better with the Gleason score than the % α2,3-SA. The combination of both markers increased the AUC up to 0.985 resulting in 100% sensitivity and 94.7% specificity to differentiate high-risk PCa from the other low and intermediate-risk PCa and BPH patients. These results suggest that both serum markers complement each other and offer an improved diagnostic tool to identify high-risk PCa, which is an important requirement for guiding treatment decisions. MDPI 2017-04-17 /pmc/articles/PMC5412429/ /pubmed/28420168 http://dx.doi.org/10.3390/ijms18040845 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ferrer-Batallé, Montserrat Llop, Esther Ramírez, Manel Aleixandre, Rosa Núria Saez, Marc Comet, Josep de Llorens, Rafael Peracaula, Rosa Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection |
title | Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection |
title_full | Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection |
title_fullStr | Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection |
title_full_unstemmed | Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection |
title_short | Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection |
title_sort | comparative study of blood-based biomarkers, α2,3-sialic acid psa and phi, for high-risk prostate cancer detection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412429/ https://www.ncbi.nlm.nih.gov/pubmed/28420168 http://dx.doi.org/10.3390/ijms18040845 |
work_keys_str_mv | AT ferrerbatallemontserrat comparativestudyofbloodbasedbiomarkersa23sialicacidpsaandphiforhighriskprostatecancerdetection AT llopesther comparativestudyofbloodbasedbiomarkersa23sialicacidpsaandphiforhighriskprostatecancerdetection AT ramirezmanel comparativestudyofbloodbasedbiomarkersa23sialicacidpsaandphiforhighriskprostatecancerdetection AT aleixandrerosanuria comparativestudyofbloodbasedbiomarkersa23sialicacidpsaandphiforhighriskprostatecancerdetection AT saezmarc comparativestudyofbloodbasedbiomarkersa23sialicacidpsaandphiforhighriskprostatecancerdetection AT cometjosep comparativestudyofbloodbasedbiomarkersa23sialicacidpsaandphiforhighriskprostatecancerdetection AT dellorensrafael comparativestudyofbloodbasedbiomarkersa23sialicacidpsaandphiforhighriskprostatecancerdetection AT peracaularosa comparativestudyofbloodbasedbiomarkersa23sialicacidpsaandphiforhighriskprostatecancerdetection |